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THE EFFECTS OF AMYLIN ON THE CLEARANCE AND AGGREGATION OF 
AMYLOID BETA IN BV-2 MICROGLIA CELL CULTURE 
 
LORENE CHUNG LEUNG 
ABSTRACT 
 Alzheimer’s disease (AD) is a neurodegenerative disease with characteristic 
amyloid, neurofibrillary tangles, and neuronal death in the brain. The major component 
of amyloid is monomeric amyloid beta (Aβ) protein, as well as its oligomers and large 
fibrils. Aβ, especially oligomeric Aβ, causes neurotoxicity. The aim of the present study 
was to investigate how Aβ is metabolized in the presence of microglia cells. 
We have used a cellular model to study the phagocytosis and degradation of Aβ 
by BV-2, a murine microglia cell line. We also examined if amylin, a pancreatic peptide, 
influences the metabolism of Aβ by BV-2 cells. Through Western blot analysis, we 
observed the phagocytosis of Aβ by BV-2 cells. In our investigation of the role of amylin, 
we observed a trend in our finding that amylin increased phagocytosis in BV-2 cells and 
decreased aggregation in the culture medium. Our data demonstrate that amylin may 
modulate microglia function in the AD brain and has potential to become therapeutic for 
the disease.  
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INTRODUCTION 
Alzheimer’s disease (AD), the sixth-leading cause of death in the United States 
and the most common cause of dementia, is a neurodegenerative disease characterized by 
a progressive decline in cognitive function (Association & others, 2017). The 2017 
annual report indicates that 5.5 million individuals in the United States are currently 
affected by the disease, of which 5.3 million are reported to be 65 years and older. With a 
growing prevalence of the aging population living with AD, there has been a pressing 
need to understand the complexities implicated in the disease pathology and the impact it 
has on symptomatology. Driven by establishment of nationwide AD centers and 
initiatives, a vast amount of groundwork from basic science to clinical research has 
strived to better understand the course and progression of the disease. The application of 
the research to clinical diagnostic criteria and potential therapeutics is ultimately an 
important goal.  
Pathology of AD 
Since the discovery of AD in 1906 (Stelzmann, Norman Schnitzlein, & Reed 
Murtagh, 1995), technologic advances in basic science research have contributed to a 
clearer perspective of the disease pathology. In particular, as highlighted by Selkoe 
(2001), the innovation of electron microscopy led to key neuropathologic observations in 
the 1960’s: the formation of extracellular senile (neuritic) plaques and intracellular 
neurofibrillary tangles, as shown in Figure 1. An ultrastructural analysis of the plaques 
revealed that the core contained amyloid fibrils, which were surrounded by large 
neuronal processes (Terry, Gonatas, & Weiss, 1964) and later identified to comprise of 
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amyloid beta (Aβ) protein (Glenner & Wong, 1984; Masters et al., 1985). The primary 
component of tangles consisted of paired helical filaments (Kidd, 1963), which contain 
microtubule-associated tau protein (Perl, 2010). These classic lesions have not only 
become diagnostic features of AD (Serrano-Pozo et al., 2011), but also the basis of 
molecular mechanisms that have helped to explain AD pathogenesis (Hardy, 2006; 
Cappai, 2016).  
At the forefront, one widely investigated mechanism within the field is the 
‘amyloid hypothesis of AD’, which focuses on the imbalance between the production and 
clearance of Aβ leading to accumulation and deposition in the form of plaques (Hardy & 
Allsop, 1991; Selkoe, 1991, Hardy & Higgins, 1992; Hardy & Selkoe, 2002).  
             
Figure 1. Hallmark structures associated with Alzheimer’s disease pathology. Two 
characteristic lesions found in AD are senile (neuritic) plaques (shown here with 
arrowheads) and neurofibrillary tangles (labeled as ‘NFT’ and shown with arrows). The 
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image shows the use of Bielschowsky silver stain, a special histological technique 
designed to visualize these structures. Adapted from Nixon (2007). 
Aβ production from the amyloidogenic pathway 
Aβ, a 4 kilodalton (kDa) peptide consisting of 39-43 amino acid residues, is 
produced by the proteolysis of the larger β-amyloid precursor protein (APP) (Kang et al., 
1987; Serpell, 2000; Murphy & LeVine, 2010). The generation of Aβ peptide fragment in 
the ‘amyloidogenic pathway’ and the prevention of Aβ production in the ‘anti-
amyloidogenic pathway’ result from different cleavage sites of APP by proteases called 
secretases (Haass et al., 2012). Figure 2 shows proteolytic processing in both pathways. 
In the amyloidogenic pathway, β-secretases first cleave APP followed by gamma (γ)-
secretases, ultimately releasing Aβ into the extracellular space (Haass, 2004). In the anti-
amyloidogenic pathway, alpha (α)-secretases first cleave within the Aβ domain of APP 
followed by γ-secretases, which then release a non-pathological 3 kDa peptide (p3) 
(Haass et al., 1993). 
A further look into the amyloidogenic pathway reveals that the production of Aβ 
peptides are mediated by the γ-secretase complex, composed of presenilin-1 or 
presenilin-2, nicastrin, anterior pharynx defective 1, and presenilin enhancer 2 (Haass & 
Selkoe, 2007; Zhang et al., 2014). Cleavage at the γ-site can occur variably, typically 
after amino acids 42 and 40, generating the 42-residue Aβ peptide (Aβ 1-42) and the 
shorter 40-residue Aβ peptide (Aβ 1-40) (Haass & Selkoe, 2007). These two peptides 
have been extensively studied using techniques of mass spectrometry (Mori et al., 1992) 
and circular dichroism spectroscopy (Walsh et al., 1999), compared using kinetic 
analyses of fibril formation based on the nucleation-dependent polymerization process 
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(Fezoui & Teplow, 2002), and visualized using electron cryo-microscopy (Schmidt et al., 
2009). While the secretion of Aβ 1-40 is more abundant within the cerebral vasculature, 
where deposits are found in the majority of capillary walls (Attems, Lintner, & Jellinger, 
2004), studies have shown the significant role of Aβ 1-42 in neuritic plaque formation 
and its greater vulnerability to aggregate which ultimately leads to neurotoxicity (Jarrett, 
Berger, & Lansbury, 1993). Vandersteen et al. (2012) confirmed this by using thioflavin 
T fluorescence to show that a longer peptide length correlates with faster aggregation. 
The heterogeneous nature of APP proteolytic processing thus produces variants of Aβ 
and the critical morphological changes that follow the secretion as part of the aggregation 
process will now be discussed. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Anti-amyloidogenic and amyloidogenic pathways. This illustration shows 
the proteolytic processing of β-amyloid precursor protein (APP). In the anti-
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amyloidogenic pathway (left panel), α-secretases cleave the middle of the Aβ domain 
(red and green regions depicting amino and carboxy-terminals, respectively) shortening 
the APP carboxy-terminal fragment (αAPP CTF) and releasing soluble amyloid precursor 
protein-α (APPsα). γ-secretases then cleave within the transmembrane domain generating 
a non-pathological truncated peptide (p3) and an intracellular domain of APP (AICD). In 
the amyloidogenic pathway (right panel), β-secretases first cleave the extracellular 
domain of APP, releasing soluble amyloid precursor protein-β (APPsβ). Subsequently, γ-
secretases cleave βAPP CTF, releasing Aβ into the lumen or extracellular space as well 
as generating AICD. Adapted from Haass et al. (2012). 
Aggregation Process and An Alternative Hypothesis 
It is noteworthy to re-emphasize that soluble Aβ from APP proteolytic processing 
can actually be physiologically normal where secretion can take place in the 
cerebrospinal fluid and the blood (Selkoe, 1994). The neurotoxicity stems from structural 
changes in Aβ that occur after the amyloidogenic pathway where soluble Aβ monomers 
ultimately convert to fibrils through intermediates called oligomers (dimers, trimers, and 
tetramers) and later protofilaments (Walsh et al.,1997; Walsh et al., 1999), as shown in 
Figure 3. Serpell (2000) reviews the model of conformational switching in secondary 
structures from soluble α-helices to highly hydrophobic β-sheets that then undergo 
polymerization to form neurotoxic fibrils.  
A discussion on the aggregation process would not be complete without 
mentioning an alternative approach to understanding Aβ neurotoxicity. While the 
‘amyloid hypothesis’ focuses on the later state of fibrils as the neurotoxic component of 
plaques in the AD brain (Hardy & Selkoe, 2002), more recent in vitro and in vivo studies 
have shown that soluble Aβ oligomers, an earlier state, actually contribute to neuronal 
dysfunction and degeneration. Kinghorn et al. (2006) examined the idea that a component 
within the plaques might be neuroprotective instead of neurotoxic. This component was 
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neuroserpin, a serine protease inhibitor of tissue plasminogen activator (tPA), which has 
implications in learning and memory. In the study, an interaction between neuroserpin 
and Aβ 1-42 was found in vitro, where Aβ 1-42 binds to neuroserpin and prevents the 
protease inhibition of tPA. Using primary cell cultures of rat embryonic cortical neurons, 
cytotoxicity levels of Aβ 1-42 decreased. In the same study, a transgenic Drosophila 
melanogaster model, wild-type (WT) neuroserpin was found to be associated with the 
embryonic lethal phenotype. However, co-expression of Aβ 1-42 and neuroserpin in WT 
flies rescued the effects of the lethal phenotype suggesting indeed an interaction between 
Aβ 1-42 and neuroserpin.  
  In vitro and in vivo studies also demonstrate the neurotoxicity of soluble Aβ 
oligomers, as reviewed by Lublin & Gandy (2010). At the molecular level, Aβ oligomers 
from multiple sources including synthetic, cell culture, and human extracts were revealed 
to disrupt glutamatergic uptake causing long-term depression (Li et al., 2009). Direct 
intrahippocampal injections of human Aβ oligomers using mouse models have also been 
shown to impair cognitive function (Cleary et al., 2005). 
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Figure 3. The aggregation process of Aβ. The figure illustrates the progression of 
secondary cross β-sheet structures that ultimately polymerize into fibrils, which then 
assemble to form plaques in AD. Adapted from Serpell (2000).  
Mechanisms of Aβ Clearance 
 While there is focus on the aforementioned production and aggregation process of 
Aβ, less attention is given to how Aβ is cleared. To date, there are multiple mechanisms 
that explain the clearance. One proposed mediator integrating these mechanisms is the 
genetic risk factor of AD, apolipoprotein E (ApoE), and ATP-binding cassette A1 
(ABCA1) transporter (Wildsmith et al., 2013). Figure 4 illustrates various key players in 
Aβ clearance, including (1) Aβ binding to ApoE receptors such as low density lipoprotein 
receptor (LDLR) or LDLR-related protein 1 (LRP1) that can clear Aβ by transport across 
the blood brain barrier (BBB); (2) insulin-degrading enzyme (IDE) that can degrade Aβ; 
and (3) microglia cells that can uptake Aβ, which is then degraded by lysosomes.  
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The role of microglia in AD 
Microglia have long been known to be resident macrophages of the central 
nervous system (Rezaie & Male, 2002) since the first description by Rio-Hortega (1939). 
The association between microglia and AD thus stems from its phagocytosis function. 
The idea that microglia can clear and uptake Aβ has been well documented in a host of 
studies from cell culture to animal models. First, in culture studies, Ard et al. (1996) 
demonstrated through immunoblotting that cultured adult rat microglia can remove 
purified human monomeric and aggregate forms of Aβ from serum-free medium. Results 
from immunostaining showed that Aβ could localize to intracellular vesicles. Kopec & 
Carroll (1998) concluded that synthetic Aβ 1-42 could induce a time- and dose-dependent 
response of phagocytosis by murine BV-2 microglia by the technique of flow cytometry 
to quantify uptake of fluorescent microspheres. However, the phagocytosis response of 
microglia in terms of its activation by various forms of Aβ is still under investigation.  
More recently, Pan et al. (2011) revealed that Aβ 1-42 fibrils enhanced 
phagocytosis response in a dose- and time-dependent manner in BV-2 microglia cells 
whereas oligomeric Aβ impaired the response. Animal studies have shown that amyloid 
cores or fibrillar Aβ (fAβ) injected into the cortex and hippocampus of rats were 
phagocytosed by microglia as fast as one week (Frautschy, Cole, & Baird, 1992) and 
more recent research incorporates proinflammatory markers to show that microglial 
phagocytosis of Aβ occurs in transgenic AD mouse models (Rojanathammanee et al., 
2015). 
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Figure 4. Mechanisms of Aβ clearance. This figure illustrates how the induction of 
apolipoprotein E (ApoE) and ATP-binding cassette A1 (ABCA1) transporter by hormone 
receptors can initiate multiple pathways of Aβ clearance. Adapted from Wildsmith et al. 
(2013). 
The association between Amylin and Aβ 
  An overview of Aβ and its mechanisms of production, aggregation, and clearance 
have been thoroughly discussed. Sharing the spotlight, however, is a gut-brain axis 
hormone that possesses many similar features as Aβ. Amylin or islet amyloid polypeptide 
(IAPP) is a 37 amino acid hormone co-secreted with insulin by pancreatic β-cells. Its 
physiological functions include lowering glucose levels and body weight, and thus has 
implications in diabetes and obesity (Hay et al., 2015). Much attention has been given to 
amylin due to its similarities with Aβ, as reviewed by Qiu & Zhu (2014): (1) folds into β-
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sheet secondary structure (Lim et al., 2008); (2) binds to same amylin receptor (AmR) 
(discussed below; Fu, Patel, & Jhamandas, 2013); and (3) can be degraded by IDE (Qiu 
et al., 1998). Amylin is also known to aggregate as fibrillar deposits in pancreatic islets 
causing β-cell failure (Westermark, Andersson, & Westermark, 2011). Both amylin and 
Aβ can form toxic soluble oligomers, which can diffuse into the brain by crossing the 
BBB (Despa & DeCarli, 2013). 
The effects of Amylin on Aβ 
At the molecular level, research has shown that the effects of amylin on Aβ are 
mediated through AmR, which structurally is the complex of the calcitonin receptor 
(CTR) dimer and Receptor activity modifying protein 3 (RAMP3) (Götz, Lim, & Eckert, 
2013). In particular, Jhamandas et al. (2011) found that electrophysiological activity was 
blocked in primary cultures of fetal human neurons treated with Aβ 1-42 and the selective 
AmR antagonist AC253. In addition to using primary cultures, APP-overexpressing 
transgenic mice (TgCRND8) were used as a model to show upregulation of CTR and 
RAMP3 in regions that showed high amyloid burden including the cortex, hippocampus, 
and basal forebrain.  
Other mouse models have demonstrated the promising effects of amylin and its 
clinical analogue, pramlintide, on AD symptomatology and pathology. Clinically, the 
analogue of amylin is known as pramlintide acetate, which was approved by the Food 
and Drug Administration in 2005 for Type 1 and Type 2 diabetes (Ryan, Jobe, & Martin, 
2005). Adler et al. (2014) showed that chronic treatment of pramlintide in senescence-
accelerated prone mouse (SAMP8) improved memory performance in the object 
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recognition task and increased synaptic protein expression in hippocampal tissue. Using 
several AD mouse models, Zhu et al. (2015) revealed that intraperitoneal injection of 
amylin in APP transgenic mice 5XFAD for 10 weeks significantly improved learning and 
memory when they were introduced to classic behavioral Y-maze and Morris water maze 
tests, as well as reduced AD pathology in the cortex, hippocampus, and thalamus.   
These positive findings from research using AD mouse models have laid the 
groundwork for human studies. Most recently, Zhu et al. (2017a) developed a pramlintide 
challenge test where individuals with normal cognition without memory complaints as 
control subjects, mild cognitive impairment, or AD were first instructed to fast overnight 
before a single subcutaneous injection of pramlintide. Glucose levels were checked and 
blood was drawn at various time points. The results showed that the challenge test had an 
effect on AD biomarkers, including observing a significant increase in plasma levels of 
Aβ 1-40 in subjects with AD. The results of the study suggest that the pramlintide 
challenge test may serve as a potential diagnostic blood test for AD in the future.  
Application of research to the clinical setting 
Translation of research to the clinical setting can often be difficult. Much of this 
comes from the heterogeneity of AD research, where there are currently numerous 
approaches that attempt to conceptualize the disease pathogenesis. Even with a heavy 
focus on Aβ alone as was previously discussed, there are also multiple mechanisms. 
Amyloid hypothesis of AD and the alternative, in which the early aggregate state of 
oligomers is neurotoxic, provide only two of the mechanistic pathways. Microglia may 
also play a critical role in the clearance of Aβ. The potential therapeutic effects of amylin 
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have created another level of understanding AD, where there may be a close interaction 
between amylin and Aβ. 
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SPECIFIC AIMS 
 
 Although there has been much support behind the dominant amyloid hypothesis 
of AD from findings in genetics studies (Selkoe, 2000), currently there are no drug 
targets for Aβ becoming therapeutic to AD yet. Since the hypothesis originated more than 
two decades ago, multiple mechanisms have helped to further explain the imbalance 
between production and clearance of Aβ. One of these includes the role of microglia and 
its phagocytosis function to clear Aβ, which could become an effective target for AD 
drug development. Using a cellular model of BV-2 murine microglia and a focus on the 
molecular technique of Western blot, the specific aims of the present study were the 
following:  
(1) To develop a working system to ensure detection of Aβ 1-42  
(2) To determine whether BV-2 microglia cells can phagocytose Aβ 1-42 
(3) To test the effects of amylin on microglia for Aβ clearance   
We investigated the effects of amylin, a hormone produced and secreted by 
pancreatic β-cells (Hay et al., 2015), on the phagocytosis and degradation of Aβ 1-42 as 
potential clearance mechanisms by BV-2 cells. Since amylin shares many similar features 
with Aβ (Qiu et al., 1998; Lim et al., 2008; Fu, Patel, & Jhamandas, 2013) , we were 
interested in the association between the two, particularly examining whether there would 
be effects of amylin on the aggregation and clearance of Aβ 1-42. At the present, while it 
is well documented that BV-2 cells can phagocytose Aβ 1-42 (Kopec & Carroll, 1998) 
and there has been extensive research on the effects of amylin on Aβ 1-42  using AD 
	 	
 14 
mouse models (Adler et al., 2014; Zhu et al., 2015), it is unclear whether there would be 
any effects of amylin on Aβ 1-42 in the presence of BV-2 cells.  
Therefore, other primary objectives of the study were the following: 
(4) To observe whether there would be an effect of amylin on the signal of Aβ 1-42, 
in terms of aggregation, in the cell culture medium  
(5)  To examine whether there would be any time-dependent and concentration 
effects of amylin on Aβ 1-42 in the cell lysate  
Given unpublished data from our laboratory highlighting the significant time- and 
dose-dependent effects of amylin on Aβ 1-42 using AD mouse models, we hypothesized 
that there would also be similar effects of amylin on Aβ 1-42 in BV-2 cells. More 
specifically, higher concentrations of amylin during a longer post-treatment incubation 
period would decrease aggregation in the culture medium and increase the clearance of 
Aβ 1-42 by BV-2 cells. Finally, the results of the culture study hope to develop a cellular 
mechanism to further understand AD pathogenesis, notably areas in clearance and 
aggregation, and highlight the connection between amylin and Aβ.  
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METHODS 
 
Preparation of Aβ 1-42 
 
0.5 µg of human Aβ 1-42 powder (AnaSpec, Inc., cat #: AS-24224) was dissolved 
in 500 µl of dimethyl sulfoxide (DMSO) (Sigma Aldrich, Co.) at a concentration of 
1µg/1µl stock solution. 40µl aliquots of dissolved Aβ 1-42 from the stock solution were 
stored at -80°C.  
Preparation of Amylin 
 
1mg of human amylin 1-37 (AnaSpec, Inc., cat#: AS-60254-1) was dissolved in 
1ml of phosphate-buffered saline (PBS) 1X for a concentration of stock solution of 
1mg/1ml. 50 µl aliquots of dissolved amylin were stored at -80°C.  
 General Experimental Protocol 
The following schematic was used for each experiment performed (Figure 5). 
       
Detection 
Autoradiography Quantitative Analysis 
Western Blot 
Gel electrophoresis Transfer Antibody probing 
Sample Preparation 
BV-2 cell treatment Cell Harvest BCA Assay 
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Figure 5. Protocol for experiment focusing on the technique of Western blotting. 
This figure outlines the necessary steps leading up to and after Western blotting including 
preparing cell lysates to quantifying protein levels. 
 
Cell Culture 
 
BV-2 murine microglia cell stock was kindly obtained from the Laboratory of 
Molecular NeuroTherapeutics (Boston University School of Medicine, Boston, MA) and 
prepared subsequently using 95% fetal bovine serum (FBS) and 5% DMSO. BV-2 cells 
were cultured in Gibco® RPMI-1640 medium (Thermo Fisher Scientific, Inc.) 
supplemented with 10% Gibco® FBS (Thermo Fisher Scientific, H1 #10438-02) and 1% 
penicillin (10,000 units/ml) /streptomycin (10,000 µg/ml) (Thermo Fisher Scientific, Inc.) 
at 37°C in a humidified incubator with 5% CO2. 
Cells with 80-90% confluency were passaged every 2 days. Subculture involved 
washing cells with PBS, detaching using Gibco® 0.25% Trypsin-EDTA 1X (Thermo 
Fisher Scientific, Inc.), and centrifuging for 300 rpm at 4°C for 5 minutes. Cells were 
resuspended in RPMI medium and maintained in petri dishes for dilution factors of 1:10, 
1:5, or 1:3. Cell morphology was examined regularly under an Olympus IX51 inverted 
microscope. 
Cell Treatment 
 
Cells with dilution factors 1:3, 1:5, and 1:10 were seeded with 50% confluency 
for 6-well plates measured using a hemocytometer (Hausser Scientific) with the 
following formula: 5 x 105 cells/ml (expected number) / [observed number of cells 
counted/number of squares used] x 104 cells/ml x 10 (dilution factor)]. Three 6-well 
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plates with respective post-treatment incubation time points of 0 minute, 30 minutes, and 
2 hours were seeded with the following groups: 
1) PBS 
2) 2.5 µM Aβ 1-42 and PBS 
3) 2.5 µM Aβ 1-42 and 10 ng/ml amylin 
4) 2.5 µM Aβ 1-42 and 100 ng/ml amylin 
5) 2.5 µM Aβ 1-42 and 1 µg/ml amylin 
6) 2.5 µM Aβ 1-42 and 10 µg/ml amylin 
For each seeded plate, cell suspension was incubated in 1ml RPMI-1640 medium 
for 24 hours with an expected 70% confluency. Before treatment, RPMI medium was 
changed to serum-free medium and ten-fold serial dilutions of amylin were prepared 
using PBS as the diluent. The volume of amylin (10 µl) treated was calculated from the 
stock concentration (1mg/1ml) with the volume of medium (1ml) incorporated in each 
well. Treatment concentrations of amylin were based on unpublished data from our lab 
proposing effects of a dose-dependent manner of amylin on Aβ 1-42 using AD mouse 
models. 2.5 µM Aβ 1-42 was calculated as 11.3 µl, also taking into account the volume of 
media in each well. Cells were then treated with PBS, amylin, and 2.5 µM Aβ 1-42 to 
respective wells (Table 1). 
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Table 1. Cell treatment of BV-2 murine microglia in 6-well cultured plate. 
1 2 3 4 5 6 
PBS 
(11.3 µl) 
2.5µM 
Aβ 1-42 
(11.3µl) 
+ PBS 
(10 µl) 
2.5µM 
Aβ 1-42 
(11.3 µl) 
+ 10 ng/ml 
amylin 
(10 µl) 
2.5µM 
Aβ 1-42 
(11.3 µl) 
+ 100 ng/ml 
amylin 
(10 µl) 
2.5µM 
Aβ 1-42 
(11.3 µl) 
+ 1 µg/ml 
amylin 
(10 µl) 
2.5µM 
Aβ 1-42 
(11.3 µl) 
+ 10 µg/ml 
amylin 
(10 µl) 
 
Cell Harvest 
After treatment at different incubation time points, medium from each well was 
collected. Cells were washed with PBS, trypsinized using the shaking method and 
harvested with serum-free media. Each sample was centrifuged for 1 minute at 13000 
rpm. Supernatant was removed and pellets were washed with ice-cold PBS, and re-
centrifuged using the same conditions. Supernatant was removed and pellets were lysed 
with 100:1 Pierce® RIPA Buffer (Thermo Fisher Scientific, Inc.): HALT™ Protease and 
Phosphatase inhibitor cocktail (100X). Centrifuge conditions were 13000 rpm for 15 
minutes. Supernatant for each sample was collected. 
Determination of Protein Concentration 
 In order to measure total Aβ 1-42 levels in cell lysates for later normalization of 
protein results, a bicinchoninic acid (BCA) assay was performed. Stock bovine serum 
albumin (BSA) was diluted as standard samples with final concentrations of 0, 25, 125, 
250, 500, 750, 1000 µg/ml for the assay. Standard and 1:5 diluted samples (10 µl) and 
their duplicates were added to 200 µl of 50:1 mixture of Pierce® BCA Reagent A to 
Reagent B in individual wells of a 96 well plate (Thermo Fisher Scientific, Inc.). The 
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plate was incubated for 30 minutes at 37°C. Finally, protein concentration was measured 
at 562 nm and a standard curve was generated from Gen5™ Microplate Reader and 
Imager Software Version 2.09 (BioTek Instruments, Inc.). 
Western Blot Analysis 
Western blot samples from cell lysates were made from 10-20 µg protein in a total 
volume ranging from 30-40 µl of 19:1 volume ratio of 2x Tricine SDS Sample Buffer 
(Invitrogen, cat # LC1676) to 2-mercaptoethanol (Sigma Aldrich, Co.) and 1x buffer. 
Samples from media were made using 10 µl of media collected post-treatment and 10 µl 
of 2x buffer. All samples from cell lysates and media were then heated at 100°C for 5 
minutes and proteins were separated using Novex™ 10-20% Tricine Gel 1.0mm x 12 
well (Invitrogen, Thermo Fisher Scientific, Inc.). For n = 7, 10 µl of samples from cell 
lysates and 3 µl from media were loaded onto the gel. 0-minute post-treatment incubation 
samples were duplicated for the design of the gels (Figure 6).  
Well 
1 2 3 4 5 6 7 8 9 10 11 12 
 
 
 
 
 
 
 
 
 
 
 
Well 
1 2 3 4 5 6 7 8 9 10 11 12 
0 minute incubation 30 minute incubation 
1= Marker 
2= 2.5µM Aβ 1-42+ PBS 
3= 2.5µM Aβ 1-42 + 10ng/ml 
amylin 
4= 2.5µM Aβ 1-42 +100ng/ml 
amylin 
5=2.5µM Aβ 1-42 + 1µg/ml 
amylin 
6=2.5µM Aβ 1-42 + 10µg/ml 
amylin 
7=PBS 
8= 2.5µM Aβ 1-42 + PBS 
9= 2.5µM Aβ 1-42 + 10ng/ml 
amylin 
10= 2.5µM Aβ 1-42 +100ng/ml 
amylin 
11= 2.5µM Aβ 1-42 + 1µg/ml 
amylin 
12= 2.5µM Aβ 1-42 + 10µg/ml 
amylin 
 
 
0 minute incubation 2 hour incubation 
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Figure 6. A representative design of gels ran by Western blot for testing the effects 
of amylin on Aβ 1-42. The figure shows 12 wells grouped by post-treatment incubation 
time. Two gels were run per experiment, showing comparisons between 0 minute and 30 
minute, and 0 minute and 2 hour incubation samples. 
 
The gels were then run using Novex™ Mini-Cell (Invitrogen, Thermo Fisher 
Scientific, Inc.) in 10% Tricine SDS Running Buffer (10X) (Novex, Life Technologies) 
at 60V for 30 minutes and increased to 100V for 1 hour (Bio-Rad Laboratories, Inc.). The 
gels were transferred to methanol-activated polyvinylidene fluoride (PVDF) membranes 
using Mini Trans-Blot® Cell (Bio-Rad Laboratories, Inc.) in 20% Transfer Buffer (10X) 
(Tris base, 0.25M, glycine, 1.92M, pH 8.4 ± 0.2) at 100V for 2 hours. After transfer, 
membranes were blocked with 5% non-fat dry milk in tris-buffered saline plus 1% Tween 
20 (TBST) 10X (American Bio, CLIA Grade). Primary antibody, Anti-Aβ 1-42 (6E10) 
(1:1000; BioLegend, cat # 803001), was added to the membranes and incubated 
overnight at 4°C. Membranes were washed three times each for 10 minutes in TBST and 
then incubated with secondary antibody, goat anti-mouse immunoglobulin G (IgG) 
conjugated to horseradish peroxidase (HRP) (1:2000; Santa Cruz Biotechnology), in 1% 
non-fat dry milk for 1 hour at room temperature. After incubation of secondary antibody, 
membranes were washed again 3 times in TBST for 10 minutes each wash. The signal of 
Aβ 1-42 in the samples was visualized using Amersham ECL™ Detection reagent (GE 
Healthcare) and exposed to HyBlot CL® autoradiography film (Denville Scientific, Inc., 
cat # E3108). 
Finally, in order to check the signal of β-actin, a 42 kDa peptide as the loading 
control, stripping buffer (Thermo Fisher Scientific, Inc.) was added to the membranes for 
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1 hour and then blocked for another hour with 5% non-fat dry milk to restore the 
membranes. Primary antibody, mouse monoclonal IgG1 β-actin (1:500; Santa Cruz 
Biotechnology) was then incubated overnight at 4°C. Membranes were washed again for 
3 times with TBST for 30 minutes and secondary antibody, anti-mouse (1:2000), was 
also used for detection. Conditions used to develop Aβ 1-42 were also applied to β-actin. 
Adjustments to General Experimental Protocol 
According to each type of experiment performed, there were several specific 
adjustments to cell treatment and Western blot protocols: 
Part I: Detection of Aβ 1-42 
 No cell treatment was performed here, but ten-fold serial dilution of Aβ 1-42 was 
performed to check whether Aβ 1-42 can be detected by Western blot (n = 1). The design 
of the gel was the following using Novex™ 10-20% Tricine Gel 1.0mm x 10 well 
(Invitrogen, Thermo Fisher Scientific, Inc.), as shown in Table 2: 
Table 2. Representative gel for detecting Aβ 1-42. 
Well 
1 
Marker 
2 
Empty 
3 
1nM 
Aβ 
1-42 
4 
10nM 
Aβ  
1-42 
5 
Empty 
6 
100nM 
Aβ  
1-42 
7 
1µM 
Aβ 
1-42 
8 
Empty 
 
Part IIa: Detection of Aβ 1-40 in Cell Lysate 
 Cells were treated with 100nM and 2.5µM Aβ 1-40 (n = 1). They were incubated 
post-treatment for 15 minute, 30 minute, 1 hour, and 2 hour. The design of the gels was 
the following: 
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Well 
1 
Marker 
2 
Empty 
3 
PBS 
4 
100nM 
Aβ  
1-40 
5 
2.5µM 
Aβ  
1-40 
 
6 
Empty 
7 
PBS 
8 
100nM 
Aβ  
1-40 
9 
2.5µM 
Aβ  
1-40 
 
10 
Empty 
 
Well 
1 
Marker 
2 
Empty 
3 
PBS 
4 
100nM 
Aβ  
1-40 
5 
2.5µM 
Aβ  
1-40 
 
6 
Empty 
7 
PBS 
8 
100nM 
Aβ  
1-40 
9 
2.5µM 
Aβ  
1-40 
 
10 
Empty 
 
 
Figure 7. A representative design of gels ran by Western blot for detection of Aβ 1-
40.  Two gels were ran for the experiment, where incubation time groups from cell 
lysates were compared. 
 
 
Part IIb: Detection of Aβ 1-42 in Cell Lysate 
 Cells were treated with 100nM and 2.5µM Aβ 1-42 (n = 1). A similar Western 
blot protocol was used as in Part IIa. Post-treatment incubation time points, however, 
were 0 minute, 30 minutes, 1 hour, 2 hours. 
Part III: Testing effects of amylin on Aβ 1-42 in Culture Medium 
 In addition to the above general protocol described in detail, there was another 
round of experiments (n = 2) performed where post-treatment incubation time points 
were 15 minute and 2 hours. Each individual gel corresponded to the time point and was 
designed by the following, as shown in Table 3: 
15 minute incubation 30 minute incubation 
1 hour incubation 2 hour incubation 
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Table 3. Representative gel for testing effects of amylin on Aβ 1-42 in Culture 
Medium.  
Well 
1 
Marker 
2 
Empty 
3 
PBS 
4 
2.5µM 
Aβ 1-
42 + 
PBS 
 
5 
2.5µM 
Aβ 1-42 
+ 
10ng/ml 
amylin 
6 
Empty 
7 
2.5µM Aβ 
1-42 
+100ng/ml 
amylin 
8 
2.5µM 
Aβ 1-
42 
+ 
1µg/ml 
amylin 
9 
2.5µM 
Aβ 1-42 
+ 
10µg/ml 
amylin 
10 
Empty 
 
 
 
Part IV: Testing effects of amylin on Aβ 1-42 in Cell Lysate 
 In addition to the above general protocol described in detail, a similar design of 
gel to that of Part III was used here for other experiments that collected cell lysate (n = 
2). 
Quantitative Analysis  
Aβ 1-42 levels were quantified and normalized to β-actin using ImageJ 1.47 
software (Schneider, Rasband, & Eliceiri, 2012). Background subtraction was taken into 
account during normalization.  
Statistical Analysis 
 Normalized quantitative data as determined with ImageJ software were averaged 
and calculated with standard error (M±SE) across experiments (n = 7) under the same 
treatment conditions and post-treatment incubation time points. Student’s t-test was 
performed for the following to further analyze for significance (p<0.05).  
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 To determine the effects of amylin on extracellular Aβ 1-42 across different 
incubation time points:  
(1) Data from peak area for monomers were averaged and compared among 0 minute 
vs. 30 minutes vs. 2 hours treatment groups, where values from 0 minute group were 
normalized as 1. 
(2) Data from peak area for oligomers (composite of dimers, trimers, and tetramers) 
were averaged and compared among 0 minute vs. 30 minutes vs. 2 hours treatment 
groups, where values from 0 minute group were normalized as 1. 
To determine the effects of amylin on intracellular Aβ 1-42 across different 
incubation time points: 
(1) Normalized Aβ-142/ β-actin ratios were averaged and compared among 0 minute 
vs. 30 minutes vs. 2 hours treatment groups 
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RESULTS 
Concentrations of Aβ 1-42 detected by Western blot  
 In order to develop a working system for experiments focused on using Western 
blot to detect Aβ and its aggregation, it was crucial to determine a range of concentrations 
that could be detected. Different concentrations of Aβ 1-42, from as low as 1 nM to as 
high as 2.5 µM, could be detected by Western blot. We found that 2.5 µM of Aβ 1-40 or 
Aβ 1-42 was the optimal concentration that can detect monomers and aggregated forms 
on Western blots (Figure 8).  Thus we chose the concentration of 2.5 µM of Aβ to be 
used in BV-2 cell culture. A time-dependent increase of phagocytosis between 15 
minutes and 2 hours post-treatment was observed (data not shown). 
The amylin effect on monomeric Aβ in the presence of microglia   
First, we conducted Western blots on the media to detect extracellular Aβ 1-42 
monomers and oligomers (Figure 8). We next quantitated data from different experiments 
focusing on Aβ 1-42 monomers and oligomers (n = 7). We observed that in the presence 
of BV-2 cells, monomeric Aβ in the media was significantly reduced after 2 hours’ 
incubation (Figures 8 and 9). Adding amylin to BV-2 cells did not influence the levels of 
monomeric Aβ in the media (Figure 9). For monomeric Aβ 1-42, we observed that co-
treatment of the highest concentration of amylin, 10µg/ml, had a significant decrease in 
the amount of extracellular monomers as incubation time increased to 2 hours (p=0.003; 
Figure 9). For 10µg/ml of amylin, there was a significant corresponding decrease of 
monomeric Aβ 1-42 from 30 minutes to 2 hours (p=0.02). Culture medium with lower 
concentrations of amylin, 100ng/ml, had a significantly lower amount of extracellular 
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monomers compared to medium without amylin as incubation  (p=0.03). For the lowest 
concentration of amylin, 10ng/ml, there was a tended increase in the amount of 
monomers in comparison to medium without amylin and medium with higher 
concentrations of amylin.  
 
Figure 8. A representative Western blot of Aβ 1-42 cell culture medium in 
increasing time points. The blot shows the effect of co-incubation with the highest 
concentration of amylin (Well 6). There is an overall decrease in aggregation, indicated 
by fewer oligomers from 0 minutes, 30 minutes, to 2 hours. The red arrow points to the 
detection of monomeric Aβ 1-42 at 4kDa.  
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Figure 9. The effect of amylin treatment on monomeric Aβ 1-42 in the culture 
medium across incubation time points. As time increases, there is a significant 
decrease (P=0.003) in extracellular monomeric Aβ 1-42 attributed to the highest 
concentration of amylin. Peak areas are represented as means ± SE, * P<0.1, ** P<0.05, 
*** P<0.01. 
 
The amylin effect on oligomeric Aβ in the presence of microglia 
 
 To further specify the effect of amylin on Aβ aggregation, from the same 
experiments (n = 7), we examined the effect of amylin on oligomeric forms of Aβ 1-42 as 
an average composite of dimers, trimers, and tetramers detected in the culture medium 
(Figures 8 and 10). In the absence of amylin, the level of oligomeric Aβ was increased 
after incubating with microglia after 30 minutes and then came back to the baseline. 
However, in the presence of amylin regardless of the concentration added, the level of 
oligomeric Aβ at 30 minutes did not show an increase compared to the baseline. As 
concentration of amylin and incubation increased, there was an overall tended decrease in 
the amount of oligomers in the medium at 2 hours’ incubation (Figure 10). 
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Correspondingly, significant decreases in the amount of oligomers as incubation 
increased to 30 minutes and later 2 hours were observed for the low concentrations of 
amylin (100ng/ml) (p=0.03) and the high concentrations of amylin (1µg/ml) (p=0.04), 
respectively. 
 
 
Figure 10. The effect of amylin treatment on oligomeric Aβ 1-42 in the culture 
medium across incubation time points. The figure illustrates that there is a trend in the 
decrease in extracellular oligomeric Aβ 1-42 with treatment of amylin as time increases. 
Peak areas are represented as means ± SE, * P<0.1, ** P<0.05. 
 
The amylin effect on intracellular Aβ in the presence of microglia 
 
Next, we examined whether there was any effect of amylin on Aβ 1-42 
internalization by BV-2 cells and found no or minimum effects of amylin on the levels of 
intracellular Aβ. After incubating the BV-2 cells with 2.5µM Aβ 1-42 until a period of 2 
hours in the absence and the presence of different concentrations of amylin, we extracted 
the cellular proteins and performed Western blots by using anti-Aβ antibody, 6E10. 
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Figure 11 summarizes the data of seven experiments. As a control and in the absence of 
amylin, the level of intracellular Aβ 1-42 tended to increase after incubating for 30 
minutes and then decreased after 2 hours (Figure 11), suggesting internalization of Aβ 1-
42 by microglia cells. We next performed subsequent experiments examining increasing 
concentrations of amylin to see if there would be any dose-dependent results. We 
quantitated data from the same experiments as the culture medium (n = 7). Overall, our 
composite data showed that amylin had no effect on internalization as incubation time 
increased to 2 hours (Figure 11).  
 
Figure 11. Averaged normalized ratios of Aβ 1-42/β-actin across treatment groups 
comparing incubation time points. The figure illustrates that there is internalization of 
Aβ 1-42 with treatment of amylin, but there is a minimal effect on the scale of 
internalization compared to Aβ alone in the cell lysate. Ratios are represented as means ± 
SE, * P<0.05. 
 
However, we observed that amylin had a tendency to inhibit internalization of Aβ 
1-42 by BV-2 cells, but did not reach statistical significance (Figures 11 and 12). 
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Figure 12. Co-incubation of highest concentration of amylin treatment increases 
internalization of amyloid beta. At the 30 minute time point, there is a significant 
increase in internalization of Aβ 1-42 (P=0.04). Ratios are represented as means ± SE.,  
* P <0.05. 
Overview of Results  
 We created a schematic of our results, in which we incorporated the following 
areas of primary interest: (1) aggregation; (2) phagocytosis/internalization; and (3) 
degradation (Figure 13). The schematic focused on time effects of extracellular and 
intracellular Aβ. Overall, as incubation time increased in our experiments, the culture 
medium showed lower amounts of monomeric and oligomeric forms of Aβ 1-42. 
Subsequently, there was a corresponding increase in monomeric Aβ 1-42 within the 
lysate, suggesting a potential mechanism for phagocytosis or internalization of Aβ 1-42 
by BV-2 cells. As incubation time progressed from 30 minutes to 2 hours, the amount of 
internalized Aβ 1-42 decreased, suggesting degradation of phagocytosed Aβ. In 
particular, Aβ degradation involving the lysosome or candidate degrading enzymes 
(Wang, Dickson, & Malter, 2006) could explain the decrease in internalized Aβ 1-42. 
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The schematic would provide a clearer understanding of cellular mechanisms of AD 
pathology involving BV-2 microglia cells. With this model in mind, three primary areas 
of interest: aggregation, phagocytosis/internalization, and degradation would further be 
discussed below incorporating the effects of amylin. 
 
 
Figure 13. A potential cellular mechanism integrating aggregation, phagocytosis, 
and degradation of amyloid beta. The schematic is an overview of 3 key pathways 
occurring within the extracellular culture medium and intracellular BV-2 microglia. 
Firstly, as time progresses, Aβ aggregates to form oligomers in the extracellular 
compartment. Secondly, BV-2 microglia cells phagocytose Aβ and its aggregated forms. 
Thirdly, Aβ is then degraded via the lysosome or degrading enzymes. EC= Extracellular, 
IC=Intracellular, N=Nucleus. 
  
	 	
 32 
DISCUSSION 
Clearance of Aβ 1-42 by microglia 
The present study used a cellular approach to investigate the phagocytosis 
function of Aβ by a microglia cell line, BV-2. Our results confirmed several established 
findings within the field regarding microglia: phagocytosis of Aβ 1-42 (Ard et al., 1996; 
Kopec & Carroll, 1998; Pan et al., 2011) and decreased Aβ 1-42 aggregation in culture 
medium in the presence of microglia cells (Ard et al.,1996). 
Furthermore, studies have explored the concept of microglial activation by 
induction of inflammatory mediators (Pan et al., 2011), binding of cell surface receptors 
located on Aβ fibrils (Bamberger et al., 2003), or induction of Aβ itself which activates 
different microglia states in response to various aggregate forms of Aβ  (Heppner, 
Ransohoff, & Becher, 2015).  
Amylin effects on Aβ aggregation in the presence of microglia cells 
 We observed that while Aβ1-42 formed oligomers in the presence of microglia, 
adding amylin inhibited oligomerization of Aβ in the presence of microglia (Figure 10). 
Several studies have demonstrated the positive effects of amylin on Aβ aggregation. 
Since amylin or IAPP has been found to co-localize with Aβ in amyloid plaques (Despa 
& DeCarli, 2013) and pancreatic deposits (Miklossy et al., 2010), structural interactions 
between amylin and Aβ have been examined. Andreetto et al. (2010) identified high-
affinity binding regions within cross-amyloid interactions, involving Aβ40-IAPP and 
Aβ42-IAPP, which suppressed self-assembly and aggregation of Aβ. Through the use of 
nuclear magnetic resonance spectroscopy, Rezaei-Ghaleh et al. (2011) confirmed that the 
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interaction between an IAPP analogue and Aβ involves a conformational change in Aβ 
which then inhibits formation of cytotoxic Aβ oligomeric aggregates. The cross 
interaction between IAPP analogue and Aβ thus is able to inhibit aggregation while the 
formation of Aβ-IAPP hetero-oligomers can only delay self-association (Yan, Velkova, 
& Kapurniotu, 2014). Most recently, using molecular dynamic simulations, Baram et al. 
(2016) showed that amylin oligomers can inhibit Aβ 1-42 aggregation. 
While the structural and molecular groundwork for understanding the interaction 
between amylin and Aβ has shown potential effects for Aβ aggregation, it is still unclear 
at the present as to how amylin affects Aβ aggregation within the context of microglia. In 
the current study, we observed that as incubation time increased, there was a tended 
decrease in aggregation, which was detected by the presence of fewer oligomers in the 
culture medium for all concentrations of amylin tested. First, this result would suggest 
that there is indeed an association between Aβ and amylin in reducing aggregation. Next, 
this would suggest a corresponding increase in internalization of Aβ oligomers within 
BV-2 microglia cells. However, only monomers were observed in the blots of cell 
lysates. Our in vitro preparation of Aβ 1-42 peptide did not control for stable 
conformations during the treatment, causing heterogeneity in our detection results. As 
diagrammed and reviewed by Benilova, Karran, & De Strooper et al. (2012), one of the 
difficulties in identifying stable oligomers is the existence of a complex, rapid 
equilibrium between Aβ monomers and its oligomeric form, which would suggest the 
need for a more precise laboratory method in generating pure synthetic oligomers. 
Moreover, Ono, Condron, & Teplow (2009) stabilized and quantified Aβ 1-40 oligomers 
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using the combined technique of photo-induced cross-linking of unmodified proteins and 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). With a defined 
assay to stabilize the structure of Aβ oligomers in vitro, additional experiments would 
then better determine the role of amylin in the process of Aβ aggregation. 
Amylin effects on Aβ internalization by microglia 
Our other primary objective was to examine the time- and dose-dependent effects 
of amylin on Aβ as suggested by promising results shown in AD mouse models (Zhu et 
al., 2015). Using a cellular approach, we observed that when adding the highest 
concentration of amylin tested (10µg/ml), there was a significant increase of cytosolic Aβ 
1-42 monomers from time of treatment to 30 minutes and a significant decrease in 
extracellular monomers as incubation time increased to 2 hours. Therefore, with the 
presence of the largest amount of amylin, time-effects were seen in the clearance of Aβ 
by internalization in BV-2 cells. Comparing the average amount of internalized Aβ with 
and without the co-incubation of amylin showed that the overall influence of amylin on 
internalization, however, was minimal. An assessment of BV-2 cell viability similar to 
the MTT reduction assay used by Pan et al. (2011) would confirm the ability of microglia 
cells to uptake Aβ even with the presence of amylin. Studies as in Lim et al. (2008) 
showed that neurotoxicity of amylin was dose-dependent and co-incubation of human 
amylin and Aβ 1-42 possessed similar toxic effects in hippocampal neurons. Therefore, 
in order to determine whether amylin has a protective or toxic effect on BV-2 microglia 
cells, a comparative assessment of cell viability should be analyzed between cells treated 
with both Aβ 1-42 and amylin and cells treated with Aβ 1-42 alone. 
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Our study showed minimum or no effects of amylin on Aβ phagocytosis by BV-2 
cells. However, the literature suggests that amylin and Aβ bind to the same receptor (Fu, 
Patel, & Jhamandas, 2013). As proposed by Qiu (2017), large amounts of Aβ would 
disturb binding of monomeric amylin to AmR, a G-protein coupled receptor involved in 
signal transduction. This disturbance would exacerbate AD pathogenesis, eventually 
leading to neuronal death. Furthermore, a more recent study investigated the effects of 
AmR (Zhu et al., 2017b) on different components of AD pathogenesis by co-injecting 
amylin with its antagonist AC253 to two different AD mouse models, 5XFAD which is 
representative of Aβ pathology and triple-transgenic mouse model of AD (3xTgAD) 
representative of both Aβ and tau. Relevant to our current study, the results showed that 
amylin significantly reduced amyloid pathology in the cortex and hippocampus of 
5xFAD mice whereas co-injection of amylin and AC253 had an attenuated effect on 
amyloid plaques.  
Amylin effects on Aβ degradation by microglia 
As we have outlined the progression of internalized Aβ 1-42 in Figure 13, we 
report that there was also degradation of Aβ. Our results showed that there was 
internalization in Aβ 1-42 by BV-2 cells at 30 minutes of treatment, but there was a 
tended decrease in the amount of Aβ 1-42 uptake as incubation period increased to 2 
hours suggesting degradation of the intracellular peptide. Similar to using a fluorescent 
dye from the in vitro study by Chung et al. (1999), our study would further incorporate a 
degradation assay to trace a potential localization of internalized Aβ 1-42 to the 
lysosome, where acidic hydrolytic enzymes potentially degrade Aβ. Since primary mouse 
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microglia cells have been shown to rapidly internalize Aβ but slowly degrade fAβ 
(Paresce, Chung, & Maxfield, 1997), it would be helpful to confirm our experimental 
results using longer incubation periods. Moreover, Majumdar et al. (2007) showed that 
primary mouse microglia cells needed to be activated by increasing the acidity of 
lysosomes in order to allow proteases to optimally work and efficiently degrade fAβ. 
Cathepsin B, a lysosomal protease, has been shown to degrade internalized Aβ in 
microglia (Halle et al., 2008). The present study would thus need to determine whether 
degradation of intracellular Aβ 1-42 is mediated by the lysosome.  
Multiple candidate degrading Aβ enzymes have been reviewed, including 
neprilysin (NEP), insulin-degrading enzyme (IDE), endothelin-converting enzyme 
(ECE), angiotensin-converting enzyme (ACE), and plasmin/urokinase-type plasminogen 
activator (uPA)/tissue plasminogen activator (tPA) (Wang, Dickson, & Malter, 2006). 
With most relevance to our study, insulin-degrading enzyme (IDE), a metalloprotease 
found in the cytosol and released by BV-2 cells, was identified in the conditioned 
medium to degrade extracellular monomeric Aβ while cell membranes were still intact. 
Insulin, substrate of IDE, was also found to competitively inhibit degradation of Aβ (Qiu 
et al., 1998). Therefore, additional experiments would incorporate IDE in Western blot 
analysis to specify a mechanism for degradation of Aβ.  
Other studies have found that IDE also degrades amylin, our other peptide of 
interest. In particular, Bennett, Duckworth, & Hamel (2000) purified IDE from rat 
skeletal muscle and showed that amylin-degrading activity was specific to IDE through 
the use of several IDE inhibitors. To date, it is not clear how amylin affects degradation 
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of Aβ in microglia. Our results illustrated that with co-incubation of amylin and Aβ, we 
noticed a tended decrease of Aβ within BV-2 cells compared to incubation of Aβ alone. 
To further study the mechanism of degradation, we would need to take into account that 
both amylin and Aβ could be degraded during incubation. The effect of amylin might 
have been attenuated contributing to an insignificant result in clearing and degrading Aβ.  
Limitations and Future Research 
The protocol contained several limitations, generating unanticipated variability 
and inconsistency. First, BV-2 is a microglia cell line. Thus it is necessary to repeat the 
experiments by using primary microglia cells. Secondly, we used Aβ1-42 which has 
tendency to aggregate. Although we used a new frozen aliquot of Aβ1-42 for each 
experiment, they might have mixed with some forms of aggregations. Since we had 
shown from previous experiments that Aβ1-40 had a lesser tendency to aggregate and can 
be internalized by BV-2 cells, we will thus test the effects of amylin on Aβ1-40 in the 
future.  
Conclusions and Implications 
We were able to develop a cellular model to identify the phagocytosis and 
degradative function of BV-2 murine microglia as a potential dual clearance mechanism 
of Aβ. The effects of amylin on clearance and aggregation of Aβ were examined by 
Western blotting. Higher concentrations of amylin were observed to increase Aβ uptake 
in the cell and decrease aggregation in the culture medium, suggesting a positive 
association between amylin and Aβ. We hope to continue this cell culture study to further 
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understand the molecular effects of amylin on Aβ and develop a drug screening system 
for AD. 
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